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Background

Classical morphea lesion

• We present a case of a 28-year-old woman with active sclerotic
plaques distributed along her neck, left flank. She had previously
failed therapy with topical steroids and methotrexate, and was started
on hydroxychloroquine 400 mg daily and
calcipotriene/betamethasone ointment 0.005% BID. Since she was
still having active lesions, she was referred to our clinic for
consultation regarding excimer laser therapy.

• Morphea, also known as localized scleroderma (LS), is an
idiopathic sclerotic inflammatory disorder that primarily affects the
skin but has the potential to involve fascia, muscle and bones.
• The disease manifests initially as erythematous lesions that
eventually transition into hypo/hyperpigmented sclerotic plaques.
• Unlike systemic sclerosis, LS spares the internal organs from
fibrosis. However, extra-cutaneous morbidities are common with
morphea and include myalgia, arthralgia, musculoskeletal
limitations, neurological symptoms, and ocular complications.

Method
• 28 years old woman with active morphea lesions on her neck and left
flank.
• Patient had one treatment at 300 mJ and experienced increased
erythema at left flank lesion for more than 24 hours.
• She then had her dose decreased and held at 260 mJ.
• We continued her current regiment of hydroxychloroquine 400 mg
daily and calcipotriene/betamethasone ointment 0.005% twice a day.

• There are three primary mechanisms involved in the development
of LS: stimulation of T cell lymphocytes causing the release of proinflammatory cytokines, dysregulation of connective tissue
metabolism, and damage to the microvasculature.
• With no cure for this disfiguring disease, therapeutic modalities
including topical regiments, immunosuppressive agents, antimalarial
medications, and phototherapy are used to manage the symptoms
and progression. While many treatments options are available, they
vary in efficacy.
• Several studies have demonstrated the benefit of phototherapy for
morphea confined to the cutaneous layer. Three central
mechanisms seem to contribute to the effectiveness of
phototherapy: breakage of DNA strands of T lymphocytes causing
apoptosis, immunomodulation of the IL-6 collagen stimulating
cytokine and IL-8 pro-inflammatory cytokine, and stimulus of
fibroblasts to produce collagenase. Studies have demonstrated the
308 nm wave length, used in the excimer laser, is the most efficient
wavelength for inducing DNA breakage in lymphocytes.
• We are reporting the use of excimer laser for active sclerotic
morphea plaques. To our
knowledge,
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Case Report

Morphea plaque of our patient after
16 treatments

Result
• After two months (16 treatment sessions), she had no progression of
her current lesions and peripheral erythema of these lesions resolved.

Conclusion
• In conclusion, we present excimer laser as an adjunct therapy
option for morphea. Being a potentially disfiguring disease with a
subset of patients failing multiple treatment regiments, we believe the
308-nm excimer laser can provide another option. The successful
management of our patient’s morphea using the 308-nm excimer
laser in addition to conventional therapy demonstrates the potential
benefit of excimer laser for morphea. To our knowledge, this is the
first description of excimer laser for the treatment of morphea.

